|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-3.60/-3.97
|
企业价值
1.52B
|
资产负债 |
每股账面净值
13.25
|
现金流量 |
现金流量率
--
|
损益表 |
收益
521.00K
|
每股收益
0.13
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/21 15:05 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. |